Risk Factors Analysis of Acute Kidney Injury in Adult Patients Receiving Extracorporeal Membrane Oxygenation

Zhixiang Mou, M. D.

RWTH Aachen University

Correspondence: zm330053@rwth-aachen.de; Tel.: (+8613702075820)

Abstract: Background: Acute kidney injury (AKI) has been reported as one of the most common complication in patients receiving extracorporeal membrane oxygenation (ECMO), the risk factors of AKI on ECMO is unknown. This meta-analysis aimed to find out the risk factors of AKI among adult patients receiving ECMO.

Methods: A literature search was performed using PubMed,Web of Science, and Embase fulfilled the pre-specified criteria until March 2020 to include studies reported the necessary clinic characteristics, then the meta-analysis was performed by STATA to get conclusion.

Results: This research is first time to provide the evidence that there is a higher risk of severe AKI (pooled OR, 2.22; 95% CI: 1.24-3.99) requiring RRT in ECMO patients with liver cirrhosis by systemic analysis, indicated that liver cirrhosis may act as a risk factor of AKI on ECMO patients.

Keywords: AKI; extracorporeal membrane oxygenation; ECMO; ECLS; risk factor

1. Introduction

Extracorporeal membrane oxygenation (ECMO) is a temporary support system for critical patients with life-threatening cardiac and/or respiratory cardiac failure, especially have failed conventional management.[1] It is a process drains blood from the venous system, pumps the blood through an oxygenator providing gas exchange, and returns the oxygenated blood to the venous (VV) or arterial (VA) circulation.[2] The indications for ECMO therapy are beyond the scope compared to 40 years ago and still keep evolving due to the progress in the ECMO equipment design and technology improvement, it is administered for treating patients with severe reversible cardiac dysfunction (acute cardiogenic shock, cardiac arrest, cardiac failure or postcardiac surgery), any potentially reversible acute respiratory failure associated with/without pneumonia (viral or bacterial), a short-term bridge to transplantation or mechanical support, awaiting recovery of organ function or a definitive therapy may effective.[3-7] Despite the improvement in survival using ECMO, acute kidney injury (AKI) is the most frequently reported problem among a number of complications[8,9] may cover the potential benefit of ECMO, and associated with poorer prognosis and increased mortality.[10-12] There are insufficient mechanism and clinical data defining the link between ECMO and AKI, a comprehensive understanding of this relationship would help us to predict, treat, and improve the clinical outcomes. Previously studies focused on the incidence and mortality of AKI among patients receiving ECMO, or discussed the factors influencing AKI patients survival on ECMO. However, it is lack of systematic analysis for the risk factors of AKI in adult patients receiving ECMO; in addition, the risk factors of severe AKI among adult patients receiving ECMO remains unclear.

The aim of this meta-analysis is to find out the risk factors of AKI and severe AKI in adult patients receiving ECMO by pooling the available data from publications.

2. Materials and Methods

2.1. Search Strategy

The protocol for this meta-analysis was registered with International Prospective Register of Systematic

Reviews (being assessed, PROSPERO ID. 177109). A systematic literature search was performed through PubMed, Web of Science, and Embase utilizing the search terms "acute kidney" OR "acute renal" AND "extracorporeal membrane oxygenation" OR "ECMO" OR "extracorporeal life support" OR "ECLS" until March 2020 to summarize the risk factors of AKI among adult patients on ECMO. Each study was evaluated for inclusion or exclusion for this analysis. No language or date restriction executed. A manual search for references of included articles was also performed. The meta-analysis was conducted and reported according to the guidelines of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA). (http://www.prismastatement.org/).

2.2. Inclusion/ Exclusion Criteria

For the purpose of this analysis, eligible studies reported the risk factors of AKI in adult patients underwent ECMO. Studies met the Population, Interventions, Comparison and Outcomes (PICO) criteria were included in the meta-analysis.

All the selected studies fulfilled the following criteria: original case-control studies provided the data of AKI requiring/not requiring renal replacement therapy (RRT) among adult patients (age $\geqslant 18$ years) during ECMO with consideration of intervention factors; reported the specific indications on ECMO; reported comprehensive clinic characteristics of AKI patients on ECMO regardless of AKI defined; reported comprehensive clinic characteristics of RRT patients receiving ECMO regardless implantation modality; with history of kidney diseases pre-ECMO patients while can not distinguished after receiving ECMO were excluded; case/case series reports< 10 patients were excluded; duplicate articles were excluded; no restriction on language/ year applied in full text written.

2.3. Data Extraction and Study Quality

A data collecting spreadsheet (Microsoft Corporation, Redmond, WA) was established to extract the following data from each included study: the first author, publication year, region, study design, number of patients, AKI/severe AKI definition, risk factors of AKI/severe AKI related ECMO. No attempt to obtain specific or missing data from the authors.

All included studies were assessed for the quality using the Newcastle-Ottawa Quality Assessment Scale (NOS) containing 3 aspects (selection, comparability and exposure) and 8 items.[13] It ranges from 0 to 9 stars, studies with a score $\geqq$ 6 were considered to meet adequate methodological quality.

2.4. AKI and severe AKI definition

RIFLE (the Risk of renal failure, Injury to the kidney, Failure of kidney function, Loss of kidney function and End stage kidney disease), AKIN (the Acute Kidney Injury Network), and KDIGO (the Kidney Disease Improving Global Outcomes) were the three major criteria to define AKI.[14-15] In this meta-analysis, AKI definition is clear once the record has defined according to one of the guidelines; severe AKI definition is that record discriminated AKI only by RRT regardless modality, AKI severity stage RIFLE-F, and KDIGO 3 (no AKIN stage provided).

2.5. risk factors related AKI

All possible risk factors potentially effect renal function during ECMO should be identifed and screened. Gender, cancer, diffuse intravascular coagulation (DIC), masssive Bleeding, intra-aortic balloon pump (IABP), post-cardiotomy, diabetes mellitus, and liver cirrhosis were pooled for further analysis due to insufficient data and inconsistent AKI definition.

2.6. Statistical Analysis

Statistical analysis was performed by STATA statistical software (version 14.0; Stata Corp, College Station, TX). In the analysis, random effects models were applied to analyzed the dichotomous data (risk factors); I^2 test (Mantel-Haenszel method) was used to evaluate heterogeneity due to probability variance between studies; the pooled odds ratio (ORs) and their corresponding 95% confidence intervals (CI) were used to evaluate the relationship between risk factors of AKI/severe AKI incidence; Z test was used to assess the significance of the pooled ORs and graphically plotted using forest plots. $\chi^2 P$ value< 0.05 or I^2 test> 50% was defined as statistically significant heterogeneity; Z test P value < 0.05 was considered statistically significant.

3. Results

3.1 Literature Search and Study Quality Assessment

The flow diagram of the studies with selection procedure and reasons for exclusion was shown in detail in Figure 1. A total of 4416 potentially eligible articles were identified from 3 databases (PubMed, n= 1445; Web of Science, n= 617; Embase, n= 2354) with the search approach until March, 2020. After excluding duplicates (2000 records), 2416 titles and abstracts were screened manually for eligibility. Then in-vitro studies, focused on pediatric or neonate population, animal studies, case reports, review articles and congress reports were excluded, 80 remaining articles were full-length reviewed for eligibility. The studies contained< 10 patients or unmatched interest outcomes were also excluded. 9 original case-control studies involving 4193 patients fulfilled the pre-specified criteria were included for the meta-analysis (Table 1). Six studies (66.7%) with a score ≧ 6 were considered good quality according to the NOS criteria (Table 2).

Table 1. study characteristics

Authors	year	region	study design	risk factors for analysis	No.of patients	AKI Definition	ECMO modes
Lin	2006	Taiwan	case-control	gender	46	RIFLE	N/A
Lee.	2015	Korea	case-control	gender, cancer, IABP	322	KDIGO	VA ECMO/VV ECMO
Antonucci	2016	Belgium	case-control	gender, cancer, DIC, massive bleeding, DM, liver cirrhosis	135	AKIN	VA ECMO/VV ECMO
lyu	2016	China	case-control	gender, IABP	84	RIFLE	VA ECMO
Delmas	2017	France	case-control	gender	60	KDIGO	VV ECMO
Chang	2017	China	case-control	gender, DIC, massive bleeding, post-cardiotomy	71	AKIN	VA ECMO/VV ECMO
Devasagayaraj	2018	USA	case-control	gender, massive bleeding	54	RRT	VV ECMO
Liao	2018	China	case-control	gender, IABP, post-cardiotomy, DM	170	KDIGO	VA ECMO/VV ECMO
Chen	2019	Taiwan	case-control	gender, cancer, IABP, post-cardiotomy, DM, liver cirrhosis	3251	RRT	N/A

Table 2. Results of quality assessment using Newcastle-Ottawa Scale for case-control studies

	Selection				Comparability	Exposure			
study	Is the case definition adequate?	Representativeness of the cases	Selection of Controls	Definition of Controls	Comparability of cases and controls on the basis of the design or analysis	Ascertainment of exposure	Same method of ascertainment for cases and controls	Non-Response rate	scores
Lin.2006	★	★	★	★	★	★		★	7
Lee. 2015	★	★	★	★	★	★		★	7
Antonucci . 2016	★	★	★	★	★	★		★	7
lyu . 2016		★	★		★	★			4
Delmas. 2017		★	★		★	★	★		5
Chang. 2017	★	★	★	★	★	★		★	7
Devasagayaraj. 2018	★	★	★	★	★	★	★		7
Liao. 2018	★	★	★	★	★	★			6
Chen. 2019		★	★		★	★			4

3.2 Study Characteristics

In this meta-analysis, seven studies (77.8%) provided the data with defined AKI/severe AKI according to the one of guidelines proposed by RIFLE, AKIN, or KDIGO. Two studies (22.2%) provided the data with defined severe AKI due to RRT. 4193 patients receiving ECMO treatment between April 2002 and May 2016 were identified as being eligible for analysis. Of these patients, 69.8% (n= 2926) male and 30.2% (n= 1267) female received ECMO; 2144 patients received ECMO due to post-cardiotomy in three studies; three studies reported 184 patients on ECMO with cancer; two studies

reported 40 patients experienced DIC during ECMO; three studies record 112 patients suffered severe bleeding; 2046 patients used IABP concomitantly with ECMO in four studies; three studies reported diabetes mellitus (DM) acted as comorbid in 893 ECMO patients, while two studies reported Liver cirrhosis reported acted as comorbid in 57 ECMO patients respectively (Table 1).

3.3 analysis risk factors of AKI in ECMO patients

A series meta-analysis were performed met the pre-defined criteria, unfortunately, the process was often accomplished only by two or three studies due to limited data reported. There was no significant difference supposed gender as a risk factor of AKI (pooled OR, 0.97; 95% CI: 0.69-1.37, $Z= 0.16$, $P= 0.870$, Figure 1a) and heterogeneity difference was not observed ($I^2= 0.0\%$, $\chi^2 P= 0.418$) among the eligible studies, indicating that gender is not a risk factor of AKI in ECMO patients.

Then the post-cardiotomy analysis was exercised as a supposed risk factor. The result showed that there was no significant difference also (pooled OR, 1.09; 95% CI: 0.47-2.55, $Z= 0.2$, $P= 0.841$, Figure 1b) and no heterogeneity difference ($I^2= 36.4\%$, $\chi^2 P= 0.21$) among the included studies, indicating that post-cardiotomy is also not a risk factor of AKI in ECMO patients.

The following analysis indicated that with cancer (pooled OR, 1.2; 95% CI: 0.56-2.58, $Z= 0.48$, $P= 0.633$, $I^2= 0.0\%$, $\chi^2 P= 0.599$, Figure 1c), experienced DIC (pooled OR, 2.1; 95% CI: 0.87-5.09, $Z= 1.65$, $P= 0.099$, $I^2= 0.0\%$, $\chi^2 P= 0.487$, Figure 1d), suffered massive/servere bleeding (pooled OR, 0.82; 95% CI: 0.44-1.52, $Z= 0.63$, $P= 0.526$, $I^2= 0.0\%$, $\chi^2 P= 0.52$, Figure 1e), used IABP concomitantly (pooled OR, 1.17; 95% CI: 0.72-1.91, $Z= 0.65$, $P= 0.52$, $I^2= 0.0\%$, $\chi^2 P= 0.323$, Figure 1f), and history of DM (pooled OR, 1.02; 95% CI: 0.42-2.47, $Z= 0.04$, $P= 0.971$, $I^2= 47.6\%$, $\chi^2 P= 0.167$, Figure 1g) were also not risk factors of AKI in ECMO patients, all heterogeneity difference were not observed.

a. <u>gender</u>

```
         Study      |    OR     [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------
lin (2006)          |  2.000      0.483     8.275         5.84
Lee (2015)          |  0.972      0.530     1.783        31.99
Antonucci (2016)    |  1.537      0.724     3.263        20.78
chang (2017)        |  0.681      0.223     2.077         9.47
liao (2018)         |  0.702      0.382     1.288        31.92
--------------------+---------------------------------------------
D+L pooled OR       |  0.972      0.690     1.370       100.00
--------------------+---------------------------------------------

  Heterogeneity chi-squared =   3.91 (d.f. = 4) p = 0.418
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   0.16 p = 0.870
```

b. post-cardiotomy

```
              Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------------
chang (2017)          | 2.162      0.549      8.520          28.52
liao (2018)           | 0.830      0.454      1.518          71.48
--------------------+---------------------------------------------------
D+L pooled OR         | 1.091      0.467      2.548         100.00
--------------------+---------------------------------------------------

  Heterogeneity chi-squared =    1.57 (d.f. = 1) p = 0.210
  I-squared (variation in OR attributable to heterogeneity) =  36.4%
  Estimate of between-study variance Tau-squared =  0.1672

  Test of OR=1 : z=   0.20 p = 0.841
```

c. cancer

```
              Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------------
Lee (2015)            | 1.044      0.412      2.646          67.31
Antonucci (2016)      | 1.615      0.425      6.130          32.69
--------------------+---------------------------------------------------
D+L pooled OR         | 1.204      0.562      2.582         100.00
--------------------+---------------------------------------------------

  Heterogeneity chi-squared =    0.28 (d.f. = 1) p = 0.599
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   0.48 p = 0.633
```

d. DIC

```
              Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------------
Antonucci (2016)      | 2.712      0.869      8.461          60.27
chang (2017)          | 1.431      0.352      5.810          39.73
--------------------+---------------------------------------------------
D+L pooled OR         | 2.104      0.870      5.088         100.00
--------------------+---------------------------------------------------

  Heterogeneity chi-squared =    0.48 (d.f. = 1) p = 0.487
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   1.65 p = 0.099
```

e. massive bleeding

```
              Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------------
Antonucci (2016)      | 0.942      0.446      1.991          67.74
chang (2017)          | 0.611      0.207      1.808          32.26
--------------------+---------------------------------------------------
D+L pooled OR         | 0.819      0.443      1.517         100.00
--------------------+---------------------------------------------------

  Heterogeneity chi-squared =    0.41 (d.f. = 1) p = 0.520
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   0.63 p = 0.526
```

f. IABP

```
              Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+---------------------------------------------------
Lee (2015)            | 0.978      0.532      1.795          64.18
liao (2018)           | 1.631      0.723      3.679          35.82
--------------------+---------------------------------------------------
D+L pooled OR         | 1.174      0.722      1.910         100.00
--------------------+---------------------------------------------------

  Heterogeneity chi-squared =    0.98 (d.f. = 1) p = 0.323
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   0.65 p = 0.518
```

g. DM

```
          Study     |    OR    [95% Conf. Interval]    % Weight
------------------+------------------------------------------------
Antonucci (2016)  |  0.654     0.269      1.588          51.13
liao (2018)       |  1.614     0.639      4.076          48.87
------------------+------------------------------------------------
D+L pooled OR     |  1.017     0.419      2.465         100.00
------------------+------------------------------------------------

  Heterogeneity chi-squared =    1.91 (d.f. = 1) p = 0.167
  I-squared (variation in OR attributable to heterogeneity) =   47.6%
  Estimate of between-study variance Tau-squared =   0.1943

  Test of OR=1 : z=   0.04 p = 0.971
```

Figure 1. analysis risk factors of AKI in ECMO patients

3.3 analysis risk factors of severe AKI in ECMO patients

The following meta-analysis were performed to find out the risk factors of severe AKI among ECMO patients. There were no significant difference supposed gender (pooled OR, 0.96; 95% CI: 0.77-1.19, I^2= 13.6%, $\chi^2 P$= 0.326, Z= 0.40, P= 0.69, Figure 2a), with cancer (pooled OR, 1.01; 95% CI: 0.75-1.37, Z= 0.08, P= 0.938, I^2= 0.0%, $\chi^2 P$= 0.701, Figure 2b), used IABP concomitantly (pooled OR, 0.98; 95% CI: 0.59-1.64, Z= 0.07, P= 0.947, I^2= 73.5%, $\chi^2 P$= 0.023, Figure 2c), and history of DM (pooled OR, 1.12; 95% CI: 0.96-1.31, Z= 1.4, P= 0.162, I^2= 0%, $\chi^2 P$= 0.931, Figure 2d) as risk factors of severe AKI, heterogeneity difference were also not observed among the eligible studies except IABP analysis, indicating these were still not risk factors of severe AKI in ECMO patients.

While, when the meta-analysis was exercised supposed live cirrhosis as a risk factor of AKI, the resulted showed that the risk of AKI was estimated 2.22 times higher (pooled OR, 2.22; 95% CI: 1.24-3.99, Z= 2.68, P= 0.007, I^2= 0.0%, $\chi^2 P$= 0.634, Figure 2e) in liver cirrhosis patients group than non-liver cirrhosis patients group, indicated that liver cirrhosis may act as a risk factor of AKI in ECMO patients.

a. gender

```
            Study       |    OR    [95% Conf. Interval]    % Weight
--------------------+------------------------------------------------
Lee (2015)          |  0.965     0.605      1.539          17.91
lin (2006)          |  3.375     0.634     17.965           1.73
Antonucci (2016)    |  0.587     0.291      1.184           8.97
lyu (2016)          |  0.530     0.183      1.537           4.15
Delmas (2017)       |  1.964     0.570      6.764           3.11
Devasagayaraj (2018)|  0.750     0.229      2.459           3.36
chen (2019)         |  1.004     0.862      1.170          60.77
--------------------+------------------------------------------------
D+L pooled OR       |  0.956     0.765      1.193         100.00
--------------------+------------------------------------------------

  Heterogeneity chi-squared =    6.95 (d.f. = 6) p = 0.326
  I-squared (variation in OR attributable to heterogeneity) =   13.6%
  Estimate of between-study variance Tau-squared =   0.0151

  Test of OR=1 : z=   0.40 p = 0.689
```

b. <u>cancer</u>

```
            Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+----------------------------------------------
Lee (2015)          |  1.014      0.499      2.061          17.80
Antonucci (2016)    |  1.600      0.523      4.891           7.17
chen (2019)         |  0.968      0.685      1.367          75.03
--------------------+----------------------------------------------
D+L pooled OR       |  1.012      0.750      1.365         100.00
--------------------+----------------------------------------------

  Heterogeneity chi-squared =   0.71 (d.f. = 2) p = 0.701
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   0.08 p = 0.938
```

c. <u>IABP</u>

```
            Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+----------------------------------------------
Lee (2015)          |  0.586      0.361      0.949          33.84
lyu (2016)          |  1.806      0.737      4.427          19.52
chen (2019)         |  1.109      0.964      1.275          46.64
--------------------+----------------------------------------------
D+L pooled OR       |  0.983      0.588      1.641         100.00
--------------------+----------------------------------------------

  Heterogeneity chi-squared =   7.55 (d.f. = 2) p = 0.023
  I-squared (variation in OR attributable to heterogeneity) =  73.5%
  Estimate of between-study variance Tau-squared =  0.1419

  Test of OR=1 : z=   0.07 p = 0.947
```

d. <u>DM</u>

```
            Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+----------------------------------------------
Antonucci (2016)    |  1.077      0.463      2.506           3.37
chen (2019)         |  1.119      0.955      1.310          96.63
--------------------+----------------------------------------------
D+L pooled OR       |  1.117      0.957      1.305         100.00
--------------------+----------------------------------------------

  Heterogeneity chi-squared =   0.01 (d.f. = 1) p = 0.931
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   1.40 p = 0.162
```

e. <u>Liver cirrhosis</u>

```
            Study     |    OR      [95% Conf. Interval]    % Weight
--------------------+----------------------------------------------
Antonucci (2016)    |  1.145      0.070     18.694           4.38
chen (2019)         |  2.291      1.261      4.164          95.62
--------------------+----------------------------------------------
D+L pooled OR       |  2.223      1.239      3.987         100.00
--------------------+----------------------------------------------

  Heterogeneity chi-squared =   0.23 (d.f. = 1) p = 0.634
  I-squared (variation in OR attributable to heterogeneity) =   0.0%
  Estimate of between-study variance Tau-squared =  0.0000

  Test of OR=1 : z=   2.68 p = 0.007
```

Figure 2. analysis risk factors of severe AKI in ECMO patients

4. Discussion

This population-based meta-analysis provided evidence that the risk of severe AKI in adult patients received ECMO with liver cirrhosis was higher than the patients received ECMO without liver cirrhosis, demonstrated that liver cirrhosis maybe a risk factor of severe AKI in adult patients received ECMO.

Rapidly increased implementation of ECMO in numerous critical care centers due to the improved the risk: benefit ratio.[25,26]AKI develops during ECMO is frequently observed and associated with poorer outcomes and higher mortality.[27-29] The pathophysiological mechanisms of AKI during ECMO remains poorly understood, it is complex, multifactorial, time dependantly and involves in both patient and ECMO related factors (figure 3). Activation of pro-inflammatory cytokines such as interleukin-1 (IL-1), IL-6, IL-8, and tumour necrosis factor-alpha (TNF-α) released from activated leukocytes due to primary disease process, combined with the interaction of blood and exposure of non-self ECMO membrane, may initiate and amplify a systemic inflammatory response leading to renal inflammation injury and microcirculation dysfunction.[26,28,30-34] Additionally, ECMO limited pulsatility, variations in ECMO circuit pressures, renal hypoperfusion from damaged cardiac function, diuretic therapy and inotrope/vasopressor administration may contribute to the hemodynamic instability and renal microcirculation dysfunction, finally lead to reduced glomerular filtration pressure and decreased GFR. [26,28,34-36]

Evidence is growing that impaired function of one organ is communicated to the dysfunction of other organs and mediated via complex mechanisms in critical illness named "organ crosstalk".[37,38] AKI is one of a typical example involving in multiple organ interactions, many systemic conditions such as vasculitis on ECMO patients invade both the liver and the kidney together, cause simultaneous liver and kidney injuries in both organs, additionally kidney may receive extra feedback from inflammation cytokine release due to decompensated cirrhosis and lead to subsequent renal vasoconstriction or structural kidney damage.[37,38,39] AKI in liver cirrhosis patients is related to the abnormal systemic hemodynamics, splanchnic arterial vasodilatation and extra-hepatic vasoconstriction,[39] ECMO implantation potentially precipitate as an acute event to further exaggerate already disturbed hemodynamics in advanced cirrhosis. Recent research reported that the most common precipitant of renal dysfunction in liver cirrhosis is bacterial infections which could product inflammatory cytokines and disturb the glomerular microcirculation or directly cause tubular cell death,[40] which is also very widespread on ECMO patients.

Thus, patients with liver cirrhosis frequently present with or act as independently risk factor of AKI and its presence regardless acute in onset or gradual in, could lead to a steady decline of renal function or chronic renal failure.

The study has several limitations. Firstly, there are still few original studies to record (< 10) the characteristics of AKI adult patients receiving ECMO. Due to the complexity of diagnosis, various unstandardized defnitions and diagnostic criteria existed throughout the records, it is only successful to extract two studies to analysis liver cirrhosis of AKI patients on ECMO and hindered the advancement of this research. However, based on the meta-analysis is very sensitive literature search and not pooled the data together simply without carefully compared defination among studies, especially the result of this analysis is consistent with the original two studies, therefore the conclusion of this study still provided certain evidence. Extra analysis could not performed (on ECMO duration, indications, modes et al) due to limited data collection. Furthermore studies are required to find out more risk factors of AKI among adult patients underwent the ECMO treatment.

Figure 3. potentially mechanisms oa AKI on ECMO patients

5. Conclusions

This research is first time to provide the evidence that there is a higher risk of severe AKI requiring RRT in ECMO patients with liver cirrhosis by systemic analysis, indicated that liver cirrhosis may act as a risk factor of AKI on ECMO patients. It is still need more studies to support the conclusion and to detect more AKI risk factors among ECMO patients.

Reference

1. Schmidt M, Stewart C, Bailey M, et al. Mechanical ventilation management during extracorporeal membrane oxygenation for acute respiratory distress syndrome: a retrospective international multicenter study. Crit Care Med 2015;43:654-64.

2. Avani R Patel, Amar R Patel, Shivank Singh, Shantanu Singh, Imran Khawaja. Applied Uses of Extracorporeal Membrane Oxygenation Therapy. Cureus. 2019 Jul; 11(7): e5163.

3. Peek GJ, Mugford M, Tiruvoipati R, et al. CESA trial collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicentre randomised controlled trial. Lancet 2009;374:1351-63.

4. Ranieri VM, Brodie D, Vincent JL. Extracorporeal organ support: from technological tool to clinical strategy supporting severe organ failure. JAMA.2017; 318:1105-1106

5. Rajan S, Wissenberg M, Folke F, et al. Association of bystander cardiopulmonary resuscitation and survival according to ambulance response times after out-of-hospital cardiac arrest. Circulation 2016;134:2095-104.

6. Butt W, Maclaren G. Extracorporeal membrane oxygenation. F1000Prime Rep 2013;5:55.

7. Brodie D, Bacchetta M. Extracorporeal membrane oxygenation for ARDS in adults. N Engl J Med 2011;365:1905-14.

8. Aubin H, Petrov G, Dalyanoglu H,et al. Four-year experience of providing mobile extracorporeal life support to out-of-center patients within a suprainstitutional networkOutcome of 160 consecutively treated patients. Resuscitation 2017; 121: 151-157.

9. D. J. Askenazi, D. T. Selewski, M. L. Paden et al., "Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation," Clinical Journal of the American Society of Nephrology, vol. 7, no. 8, pp. 1328–1336, 2012.

10. C.-Y. Lin, F.-C. Tsai, Y.-C. Tian et al., "Evaluation of outcome scoring systems for patients on extracorporeal membrane oxygenation," Te Annals of Toracic Surgery, vol. 84, no. 4, pp.1256–1262, 2007

11. C.-C. Hsiao, C.-H. Chang, P.-C. Fan et al., "Prognosis of patients with acute respiratory distress syndrome on extracorporeal membrane oxygenation: the impact of urine output on mortality," The Annals of Toracic Surgery, vol. 97, no. 6, pp. 1939–1944, 2014.

12. J. T. Kielstein, A. M. Heiden, G. Beutel et al., "Renal function and survival in 200 patients undergoing ECMO therapy," Nephrology Dialysis Transplantation, vol. 28, no. 1, pp. 86–90,2013.

13. Claudio Luchini, Brendon Stubbs, Marco Solmi, Nicola Veronese. Assessing the quality of studies in meta-analyses: Advantages and limitations of the Newcastle Ottawa Scale. World J Meta-Anal 2017;5:80-84.

14. Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P, Acute Dialysis Quality Initiative workgroup. Acute renal failure e definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) group. Crit Care 2004;8(4):R204e12.

15. Mehta RL, Kellum JA, Shah SV, Molitoris BA, Ronco C, Warnock DG, et al. Acute Kidney Injury Network: report of an initiative to improve outcomes in acute kidney injury. Crit Care 2007;11(2):R31.

25. Guglin M, Zucker MJ, Bazan VM, et al. Venoarterial ECMO for Adults: JACC Scientific Expert Panel. J Am Coll Cardiol 2019;73:698-716.

26. Kilburn DJ, Shekar K, Fraser JF. The Complex Relationship of Extracorporeal Membrane Oxygenation and Acute Kidney Injury: Causation or Association? Biomed Res Int 2016;2016:1094296.

27. Lin CY, Tsai FC, Tian YC, Jenq CC, Chen YC, Fang JT, et al.

Evaluation of outcome scoring systems for patients on extracorporeal membrane oxygenation. Ann Thorac Surg 2007;84:1256e62.

28. Chen CY, Tsai FC, Fang JT, Yang CW. Acute kidney injury in adults receiving extracorporeal membrane oxygenation. J Formos Med Assoc 2014;113:778e85.

29. D. J. Askenazi, D. T. Selewski, M. L. Paden et al., "Renal replacement therapy in critically ill patients receiving extracorporeal membrane oxygenation," Clinical Journal of the American Society of Nephrology, vol. 7, no. 8, pp. 1328–1336, 2012.

30. A. B. Kumar and M. Suneja, "Cardiopulmonary bypassassociated acute kidney injury," Anesthesiology, vol. 114, no. 4, pp. 964–970, 2011.

31. M. D. Okusa, "Te inflammatory cascade in acute ischemic renal failure," Nephron, vol. 90, no. 2, pp. 133–138, 2002.

32. B. B. Ratliff, M. M. Rabadi, R. Vasko, K. Yasuda, and M. S. Goligorsky, "Messengers without borders: mediators of systemic inflammatory response in AKI," Journal of the American Society of Nephrology, vol. 24, no. 4, pp. 529–536, 2013.

33. C. Chelazzi, G. Villa, P. Mancinelli, A. De Gaudio, and C. Adembri, "Glycocalyx and sepsis-induced alterations in vascular permeability," Critical Care, vol. 19, no. 1, article 26, 2015.

34. Villa G, Katz N, Ronco C. Extracorporeal Membrane Oxygenation and the Kidney. Cardiorenal Med. 2015 Dec;6(1):50-60. doi: 10.1159/000439444. Epub 2015 Oct 17.

35. C.-L. Leong, W. P. Anderson, P. M. O'Connor, and R. G. Evans, "Evidence that renal arterial-venous oxygen shunting contributes to dynamic regulation of renal oxygenation," The American Journal of Physiology-Renal Physiology, vol. 292, no.6, pp. F1726–F1733, 2007.

36. R. G. Evans, B. S. Gardiner, D. W. Smith, and P. M. O'Connor,"Intrarenal oxygenation: unique challenges and the biophysical basis of homeostasis," American Journal of Physiology—Renal Physiology, vol. 295, no. 5, pp. F1259–F1270, 2008.

37. Vincent JL, Sakr Y, Sprung CL et al (2006) Sepsis in European intensive care units: results of the SOAP study. Crit Care Med 34:344–353

38. Husain-Syed F, Ricci Z, Brodie D et al. Extracorporeal organ support (ECOS) in critical illness and acute kidney injury: from native to artificial organ crosstalk. Intensive Care Med. 2018 Sep;44(9):1447-1459.

39. Acute kidney injury in liver cirrhosis: new definition and application

40. Gomez H, Ince C, De Backer D, Pickkers P, Payen D, Hotchkiss J, et al. A unified theory of sepsis-induced acute kidney injury: inflammation, microcirculatory dysfunction, bioenergetics, and the tubular cell adaptation to injury. Shock 2014;41:3-11